Ascletis Pharma Inc. said its ordinary shares listed on The Stock Exchange of Hong Kong Limited were added to the eligible securities lists for both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Sept. 7, 2026. Eligible investors in the Chinese Mainland can now trade the shares through the Hong Kong Stock Connect channel. Ascletis said the inclusion reflects market recognition of its investment value and growth prospects, and expects it to broaden the shareholder base, improve trading liquidity and support long-term innovation-driven and sustainable growth. The company is a fully integrated biotechnology developer focused on potentially best-in-class and first-in-class treatments for metabolic diseases.